Fresenius Charts Aggressive Growth Path Following Restructuring Success

Fresenius posts 7% revenue growth and 12% EPS rise in 2025, increases dividend, and launches 'Rejuvenate' strategy focused on biopharma and digital healthcare innovation.

The extensive, multi-year transformation at healthcare giant Fresenius is now yielding concrete financial results. Having concluded a challenging period of portfolio adjustments, the company is pivoting decisively toward an expansionary strategy. Bolstered by a surprisingly robust annual report and a new strategic phase dubbed "Rejuvenate," management is intent on securing a leadership position in healthcare technology.

Financial Health Restored, Dividend Increased

A clear operational turnaround is evidenced by the final figures for the 2025 fiscal year, released on Monday. The group achieved organic revenue growth of 7%, reaching €22.6 billion. Even more striking was the 12% currency-adjusted rise in adjusted earnings per share, which climbed to €2.87.

This strengthened performance has prompted the board to propose an increased dividend of €1.05 per share. A key milestone for financial resilience has been reached in debt reduction: the net debt-to-EBITDA ratio now stands at 2.7x, comfortably below the original target ceiling of 3.5x. This improved leverage provides Fresenius with enhanced capacity to fund investments in high-growth markets.

Leadership Stability and Forward Guidance

The company's strategic direction is backed by continuity in its executive suite. The supervisory board has extended the contract of CEO Michael Sen ahead of schedule, securing his leadership for an additional five years until 2031. Furthermore, Christian Pawlu is slated to join the executive board on July 1, 2026, with a mandate to strengthen the market position of the hospital operator Helios.

Looking ahead to fiscal 2026, management is targeting organic revenue growth in a range of 4% to 7%. Analysts at investment bank Jefferies have reaffirmed their buy recommendation, citing a price target of €55. Market experts note that the biopharma division holds particular potential to make a growing contribution to operating profit, provided global supply chains remain stable amid ongoing geopolitical uncertainty.

Strategic Pivot to Biopharma and Digital Innovation

With the completion of its dialysis unit deconsolidation and exit from Vamed, Fresenius is fully focused on its "Rejuvenate" agenda. The future roadmap involves significant investment in digitalization and technological innovation, primarily within its Helios hospitals and Fresenius Kabi units. A deepened partnership with software firm SAP is expected to drive efficiencies in clinical care and biopharmaceutical manufacturing.

Within the group, the biopharma business under Fresenius Kabi has emerged as a powerful growth engine. It recorded an exceptional organic revenue surge of 51% last year, supplying the momentum required to fuel the company's renewed strategic offensive.